{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:34:41Z","timestamp":1793504081020,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Partnership of Siemens and University Medical Centre Groningen","award":["PUSH MO24.00027"],"award-info":[{"award-number":["PUSH MO24.00027"]}]},{"DOI":"10.13039\/501100005075","name":"Universitair Medisch Centrum Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09032212110044"],"award-info":[{"award-number":["09032212110044"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.pharmthera.2025.108891","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:08:29Z","timestamp":1748430509000},"page":"108891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis"],"prefix":"10.1016","volume":"272","author":[{"given":"Emma C.A.","family":"Vreeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janesh","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette K.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2025.108891_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2023.100566","article-title":"Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: A prospective nationwide cohort study in the United States","volume":"25","author":"Adegunsoye","year":"2023","journal-title":"The Lancet Regional Health - Americas"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jprot.2018.02.027","article-title":"Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis","volume":"189","author":"\u00c5hrman","year":"2018","journal-title":"Journal of Proteomics"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10787-022-01027-6","article-title":"Pirfenidone and post-Covid-19 pulmonary fibrosis: Invoked again for realistic goals","volume":"30","author":"Al-Kuraishy","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/atm.atm_7_23","article-title":"Post-COVID-19 pulmonary fibrosis: An ongoing concern","volume":"18","author":"Alrajhi","year":"2023","journal-title":"Annals Of Thoracic Medicine"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0025","article-title":"Post COVID-19 pulmonary fibrosis; a meta-analysis study","volume":"77","author":"Amin","year":"2022","journal-title":"Annals of Medicine and Surgery"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1148\/radiol.2283030726","article-title":"Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience","volume":"228","author":"Antonio","year":"2003","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108891_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257016","article-title":"Development of ACE2 autoantibodies after SARS-CoV-2 infection","volume":"16","author":"Arthur","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/diagnostics14060621","article-title":"Short- and long-term chest-CT findings after recovery from COVID-19: A systematic review and Meta-analysis","volume":"14","author":"Babar","year":"2024","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0045","first-page":"218","article-title":"Clinical and morphological features of lung injury long-term after SARS-CoV-2 recovery","volume":"96","author":"Baimakanova","year":"2024","journal-title":"Terapevti\u010deskij Arhiv"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109676","article-title":"Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients","volume":"138","author":"Balbi","year":"2021","journal-title":"European Journal of Radiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-024-03144-0","article-title":"Biomarkers of tissue remodelling are elevated in serum of COVID-19 patients who develop interstitial lung disease - an exploratory biomarker study","volume":"24","author":"Breisnes","year":"2024","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-02987-8","article-title":"Three-year outcomes of post-acute sequelae of COVID-19","author":"Cai","year":"2024","journal-title":"Nature Medicine."},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108891_bb0065","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/ijms19051294","article-title":"TGF-\u03b2 and the tissue microenvironment: Relevance in fibrosis and Cancer","volume":"19","author":"Caja","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0070","first-page":"22","article-title":"S31 the novel coronavirus SARS-CoV-2 binds RGD integrins and upregulates avb3 integrins in Covid-19 infected lungs","volume":"76","author":"Calver","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbi.2023.03.022","article-title":"COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis","volume":"111","author":"Ceban","year":"2023","journal-title":"Brain, Behavior, and Immunity"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cpdd.1040","article-title":"A randomized phase 1 evaluation of Deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases","volume":"11","author":"Chen","year":"2021","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/jcmm.13992","article-title":"IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis","volume":"23","author":"Chen","year":"2018","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108891_bb0090","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-14-3193","article-title":"A hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis","volume":"21","author":"Choi","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0095","article-title":"Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment","volume":"40","author":"Cilli","year":"2023","journal-title":"Sarcoidosis, Vasculitis and Diffuse Lung Diseases"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108891_bb0100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11604-021-01120-w","article-title":"Ground-glass opacity (GGO): A review of the differential diagnosis in the era of COVID-19","volume":"39","author":"Cozzi","year":"2021","journal-title":"Japanese Journal of Radiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2018","journal-title":"Nature Reviews Microbiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108891_bb0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217199120","article-title":"Innate immune cell activation causes lung fibrosis in a humanized model of long COVID","volume":"120","author":"Cui","year":"2023","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0115","article-title":"Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge","volume":"182","author":"Ekbom","year":"2021","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.es.14.110183.002341","article-title":"Host-parasite relations, vectors, and the evolution of disease severity","volume":"14","author":"Ewald","year":"1983","journal-title":"Annual Review of Ecology and Systematics"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153419","article-title":"Endothelial-mesenchymal transition in COVID-19 lung lesions","volume":"221","author":"Falleni","year":"2021","journal-title":"Pathology - Research And Practice"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108891_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.838","article-title":"Proteomic profiling of lung diffusion impairment in the recovery stage of SARS-CoV-2\u2013induced ARDS","volume":"12","author":"Garc\u00eda-Hidalgo","year":"2022","journal-title":"Clinical and Translational Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0135","doi-asserted-by":"crossref","first-page":"00108","DOI":"10.1183\/23120541.00108-2021","article-title":"Benefits of pulmonary rehabilitation in COVID-19: A prospective observational cohort study","volume":"7","author":"Gloeckl","year":"2021","journal-title":"ERJ Open Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/thx.2004.040022","article-title":"Challenges in pulmonary fibrosis {middle dot} 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias","volume":"62","author":"Gotway","year":"2007","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0145","article-title":"Lung fibrosis: An undervalued finding in COVID-19 pathological series","volume":"21","author":"Grillo","year":"2021","journal-title":"Lancet. Infectious Diseases\/The Lancet. Infectious Diseases"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108891_bb0150","doi-asserted-by":"crossref","first-page":"L864","DOI":"10.1152\/ajplung.00128.2009","article-title":"Abrogation of TGF-\u03b21-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition","volume":"297","author":"Guo","year":"2009","journal-title":"AJP Lung Cellular And Molecular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1165\/rcmb.2009-0031OC","article-title":"Endothelial\u2013Mesenchymal transition in Bleomycin-Induced pulmonary fibrosis","volume":"43","author":"Hashimoto","year":"2009","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0160","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000533606","article-title":"TGF-\u03b21 inhibition of ACE2 mediated by miRNA uncovers novel mechanism of SARS-CoV-2 pathogenesis","volume":"15","author":"Hejenkowska","year":"2023","journal-title":"Journal of Innate Immunity"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01303-24","article-title":"SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study","author":"Hellman","year":"2024","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108891_bb0170","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.29245\/2689-999X\/2019\/2.1149","article-title":"Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial\/fibroblastic cross-talk","volume":"3","author":"Hill","year":"2019","journal-title":"Journal Of Lung Health And Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin \u03b1v\u03b26 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0185","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/resp.14056","article-title":"High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis","volume":"26","author":"Hoyer","year":"2021","journal-title":"Respirology"},{"issue":"10223","key":"10.1016\/j.pharmthera.2025.108891_bb0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0195","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jinf.2020.09.027","article-title":"The potential indicators for pulmonary fibrosis in survivors of severe COVID-19","volume":"82","author":"Huang","year":"2021","journal-title":"Journal Of Infection\/The Journal Of Infection"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0200","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1378\/chest.128.4.2247","article-title":"The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors","volume":"128","author":"Hui","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109631","article-title":"Mathematical modeling of impacts of patient differences on renin-angiotensin system and applications to COVID-19 lung fibrosis outcomes","volume":"186","author":"Islam","year":"2025","journal-title":"Computers in Biology and Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06642-5","article-title":"Research progress of post-acute sequelae after SARS-CoV-2 infection","volume":"15","author":"Jiao","year":"2024","journal-title":"Cell Death and Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0215","article-title":"Ventilator-induced lung injury results in oxidative stress response and mitochondrial swelling in a mouse model. Laboratory","volume":"38","author":"Joelsson","year":"2022","journal-title":"Animal Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0220","doi-asserted-by":"crossref","first-page":"L304","DOI":"10.1152\/ajplung.00332.2023","article-title":"The lung extracellular matrix protein landscape in severe early-onset and moderate chronic obstructive pulmonary disease","volume":"327","author":"Joglekar","year":"2024","journal-title":"AJP Lung Cellular And Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.995051","article-title":"Highway to heal: Influence of altered extracellular matrix on infiltrating immune cells during acute and chronic lung diseases","volume":"13","author":"Joglekar","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0230","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36354","article-title":"Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis","volume":"7","author":"Jones","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1295457","article-title":"Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: A nationwide population-based cohort study","volume":"11","author":"Kim","year":"2024","journal-title":"Frontiers in Public Health"},{"issue":"35","key":"10.1016\/j.pharmthera.2025.108891_bb0240","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1073\/pnas.0605669103","article-title":"Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix","volume":"103","author":"Kim","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108891_bb0245","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1164\/rccm.202206-1107IM","article-title":"\u03b1v\u03b26 integrin positron emission tomography of lung fibrosis in idiopathic pulmonary fibrosis and long COVID-19","volume":"207","author":"Kimura","year":"2023","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7985","key":"10.1016\/j.pharmthera.2025.108891_bb0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-023-06651-y","article-title":"Distinguishing features of long COVID identified through immune profiling","volume":"623","author":"Klein","year":"2023","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108891_bb0255","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.3390\/ijms231911212","article-title":"Role of mesenchymal stem cells and extracellular vesicles in idiopathic pulmonary fibrosis","volume":"23","author":"Kletukhina","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0260","series-title":"Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail","author":"Lai","year":"2021"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108891_bb0265","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0270","doi-asserted-by":"crossref","first-page":"2004125","DOI":"10.1183\/13993003.04125-2020","article-title":"Interstitial lung disease increases susceptibility to and severity of COVID-19","volume":"58","author":"Lee","year":"2021","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06881-3","article-title":"Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15 years","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0280","article-title":"Recent advances in TGF-\u03b2 signaling pathway in COVID-19 pathogenesis: A review","volume":"107236","author":"Majidpour","year":"2024","journal-title":"Microbial Pathogenesis"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0285","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.arbres.2023.01.001","article-title":"Impact of COVID-19 infection on patients with preexisting interstitial lung disease: A Spanish multicentre study","volume":"59","author":"Mart\u00ednez-Besteiro","year":"2023","journal-title":"Archivos de Bronconeumolog\u00eda"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0295","series-title":"25 juli","author":"Martinez-Pitre","year":"2023"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0300","doi-asserted-by":"crossref","first-page":"L257","DOI":"10.1152\/ajplung.00238.2020","article-title":"Healing after COVID-19: Are survivors at risk for pulmonary fibrosis?","volume":"320","author":"McDonald","year":"2020","journal-title":"AJP Lung Cellular And Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797292","article-title":"Idiopathic pulmonary fibrosis: An update on pathogenesis","volume":"12","author":"Mei","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0310","series-title":"Diffusing Capacity of the Lungs for Carbon Monoxide","author":"Modi","year":"2024"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108891_bb0315","doi-asserted-by":"crossref","first-page":"12955","DOI":"10.3390\/ijms222312955","article-title":"Involvement of the ACE2\/Ang-(1\u20137)\/MasR Axis in pulmonary fibrosis: Implications for COVID-19","volume":"22","author":"Morganstein","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379570","article-title":"Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: An explorative study","volume":"15","author":"Murphy","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0325","article-title":"Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-\u03b2 signalling in COVID-19 survivors","volume":"266","author":"Murthy","year":"2021","journal-title":"Life Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108891_bb0330","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplantation"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253347","article-title":"SARS-CoV-2 uses major endothelial integrin \u03b1v\u03b23 to cause vascular dysregulation in-vitro during COVID-19","volume":"16","author":"Nader","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01925-y","article-title":"The role of epithelial-mesenchymal transition in pulmonary fibrosis: Lessons from idiopathic pulmonary fibrosis and COVID-19","volume":"22","author":"Niayesh-Mehr","year":"2024","journal-title":"Cell Communication and Signaling"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46733-5","article-title":"Collagen type XIV is proportionally lower in the lung tissue of patients with IPF","volume":"13","author":"Nizamoglu","year":"2023","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102922","article-title":"Receptor-binding domain of SARS-CoV-2 is a functional \u03b1v-integrin agonist","volume":"299","author":"Norris","year":"2023","journal-title":"Journal of Biological Chemistry"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2025.108891_bb0355","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"European Journal of Pharmacology"},{"issue":"25","key":"10.1016\/j.pharmthera.2025.108891_bb0360","doi-asserted-by":"crossref","first-page":"16872","DOI":"10.1074\/jbc.M809348200","article-title":"Latent transforming growth factor \u03b2-binding proteins and Fibulins compete for Fibrillin-1 and exhibit exquisite specificities in binding sites","volume":"284","author":"Ono","year":"2009","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0365","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respiratory Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0370","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-025-03098-9","article-title":"Extracellular matrix turnover in severe COVID-19 is reduced by corticosteroids","volume":"26","author":"Pillay","year":"2025","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-0716-1382-5_6","article-title":"Myofibroblast TGF-\u0392 activation measurement in vitro","author":"Porte","year":"2021","journal-title":"Methods in Molecular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108891_bb0380","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108891_bb0385","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1074\/jbc.R400029200","article-title":"Latent transforming growth factor-\u03b2 (TGF-\u03b2) binding proteins: Orchestrators of TGF-\u03b2 availability","volume":"280","author":"Rifkin","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0390","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM). (2021). MERS-Coronavirus. Retrieved from https:\/\/www.rivm.nl\/en\/mers-coronavirus. Accessed January 11, 2025."},{"issue":"52","key":"10.1016\/j.pharmthera.2025.108891_bb0395","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1117988108","article-title":"Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition","volume":"108","author":"Rock","year":"2011","journal-title":"Proceedings of The National Academy of Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050093","article-title":"MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"5","author":"Rosas","year":"2008","journal-title":"PLoS Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26154-6","article-title":"SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers","volume":"12","author":"Rovida","year":"2021","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0410","doi-asserted-by":"crossref","DOI":"10.1038\/srep06383","article-title":"Absence of fibromodulin affects matrix composition, collagen deposition and cell turnover in healthy and fibrotic lung parenchyma","volume":"4","author":"Rydell-T\u00f6rm\u00e4nen","year":"2014","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0415","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.arbres.2021.08.014","article-title":"Lung function, radiological findings and biomarkers of Fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge","volume":"58","author":"Safont","year":"2022","journal-title":"Archivos de Bronconeumolog\u00eda"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108891_bb0420","doi-asserted-by":"crossref","first-page":"14959","DOI":"10.3390\/ijms232314959","article-title":"Pulmonary fibrosis as a result of acute lung inflammation: Molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches","volume":"23","author":"Savin","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108891_bb0425","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1111\/febs.15651","article-title":"The structural basis of accelerated host cell entry by SARS-CoV-2\u2020","volume":"288","author":"Seyran","year":"2020","journal-title":"FEBS Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108891_bb0430","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1164\/rccm.200912-1840OC","article-title":"The angiotensin-converting enzyme 2\/angiogenesis-(1\u20137)\/mas Axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension","volume":"182","author":"Shenoy","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0435","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86002","article-title":"Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC)","volume":"12","author":"Sherif","year":"2023","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0440","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1165\/rcmb.2009-0232OC","article-title":"The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor\u2013\u03b21 Synergistically Induce Epithelial\u2013Mesenchymal Transition in Lung Epithelial Cells","volume":"44","author":"Sides","year":"2010","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0445","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/jcm12010342","article-title":"Soluble ITGaM and ITGb2 integrin subunits are involved in long-term pulmonary complications after COVID-19 infection","volume":"12","author":"Siekacz","year":"2023","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0450","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.15291","article-title":"ACE2 (angiotensin-converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic","volume":"76","author":"South","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0455","article-title":"Will COVID-19 become mild, like a cold?","volume":"152","author":"Stewart","year":"2024","journal-title":"Epidemiology and Infection"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0460","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jmv.25735","article-title":"Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis","volume":"92","author":"Sun","year":"2020","journal-title":"Journal of Medical Virology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108891_bb0465","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.200903-0322OC","article-title":"Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis","volume":"180","author":"Tanjore","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0470","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/17476348.2021.1916472","article-title":"Pulmonary fibrosis secondary to COVID-19: A narrative review","volume":"15","author":"Tanni","year":"2021","journal-title":"Expert Review of Respiratory Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108891_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158047","article-title":"Amplification of TGF\u03b2 induced ITGB6 gene transcription may promote pulmonary fibrosis","volume":"11","author":"Tatler","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0480","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1513\/pats.201201-003AW","article-title":"TGF-\u03b2 activation and lung fibrosis","volume":"9","author":"Tatler","year":"2012","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108891_bb0485","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a definition of Postacute sequelae of SARS-CoV-2 infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108891_bb0490","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14151","article-title":"Impact of COVID-19 on long-term lung function in lung transplant recipients: A single-center retrospective cohort study","volume":"25","author":"Touilloux","year":"2023","journal-title":"Transplant Infectious Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0495","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.202010-3823LE","article-title":"High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19","volume":"203","author":"Van Gassel","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0500","doi-asserted-by":"crossref","first-page":"00848","DOI":"10.1183\/23120541.00848-2020","article-title":"Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients","volume":"7","author":"Van Lier","year":"2021","journal-title":"ERJ Open Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0505","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.99","article-title":"Focusing on the long-term recovery of severe acute respiratory syndrome coronavirus 2 infection: Clinically relevant observations","volume":"2","author":"Wang","year":"2022","journal-title":"Clinical And Translational Discovery"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101833","article-title":"Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation","volume":"58","author":"Wang","year":"2019","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0515","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biocel.2016.12.005","article-title":"Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis","volume":"83","author":"Westergren-Thorsson","year":"2016","journal-title":"The International Journal Of Biochemistry & Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0520","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-\u03b2-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"AJP Lung Cellular And Molecular Physiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0525","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/his.14838","article-title":"Increase of mast cells in COVID-19 pneumonia may contribute to pulmonary fibrosis and thrombosis","volume":"82","author":"Wismans","year":"2022","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0530","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"Journal Of Pharmacology And Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0535","author":"World Health Organization (WHO)"},{"issue":"45","key":"10.1016\/j.pharmthera.2025.108891_bb0540","doi-asserted-by":"crossref","first-page":"28336","DOI":"10.1073\/pnas.2018030117","article-title":"Transcriptional and proteomic insights into the host response in fatal COVID-19 cases","volume":"117","author":"Wu","year":"2020","journal-title":"Proceedings Of The National Academy Of Sciences Of The United States Of America"},{"issue":"32","key":"10.1016\/j.pharmthera.2025.108891_bb0545","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1016\/j.vaccine.2022.05.090","article-title":"The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study","volume":"40","author":"Wynberg","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108891_bb0550","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2353\/ajpath.2009.080160","article-title":"Lysophosphatidic Acid Induces \u03b1v\u03b26 Integrin-Mediated TGF-\u03b2 Activation via the LPA2 Receptor and the Small G Protein G\u03b1q","volume":"174","author":"Xu","year":"2009","journal-title":"American Journal Of Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108891_bb0555","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1083\/jcb.200611044","article-title":"Absence of integrin-mediated TGF\u03b21 activation in vivo recapitulates the phenotype of TGF\u03b21-null mice","volume":"176","author":"Yang","year":"2007","journal-title":"The Journal Of Cell Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108891_bb0560","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.stemcr.2018.09.012","article-title":"Connexin 43-Mediated Mitochondrial Transfer of iPSC-MSCs Alleviates Asthma Inflammation","volume":"11","author":"Yao","year":"2018","journal-title":"Stem Cell Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108891_bb0565","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-1299-0","article-title":"Periostin plays a critical role in the cell cycle in lung fibroblasts","volume":"21","author":"Yoshihara","year":"2020","journal-title":"Respiratory Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0570","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jmv.26634","article-title":"Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19","volume":"93","author":"Zhang","year":"2020","journal-title":"Journal Of Medical Virology"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0575","article-title":"Single cell meta-analysis of EndMT and EMT state in COVID-19","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108891_bb0580","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pccm.2022.12.002","article-title":"Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?","volume":"1","author":"Zheng","year":"2023","journal-title":"Chinese Medical Journal Pulmonary And Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2025.108891_bb0585","article-title":"Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis","volume":"9","author":"Zhou","year":"2022","journal-title":"Frontiers in Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108891_bb0590","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1002\/jcp.24094","article-title":"Specificity of latent TGF-\u03b2 binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin","volume":"227","author":"Zilberberg","year":"2012","journal-title":"Journal Of Cellular Physiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108891_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248957","article-title":"The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT","volume":"16","author":"Zou","year":"2021","journal-title":"PloS One"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:06:44Z","timestamp":1777493204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":119,"alternative-id":["S0163725825001032"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108891","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108891"}}